How to improve cancer care by use of guidelines and quality registers

Authors

DOI:

https://doi.org/10.2340/sju.v59.42272

Abstract

N/A

Downloads

Download data is not yet available.

References

Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265–273. https://doi.org/10.1080/21681805.2022.2094462 DOI: https://doi.org/10.1080/21681805.2022.2094462

Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. Scand J Urol. 2022;56(4):278–284. https://doi.org/10.1080/21681805.2022.2093396 DOI: https://doi.org/10.1080/21681805.2022.2093396

Liedberg F, Kjellström S, Lind AK, et al. Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma. Scand J Urol. 2022;56(2):137–146. https://doi.org/10.1080/21681805.2022.2041086 DOI: https://doi.org/10.1080/21681805.2022.2041086

Abuhasanein S, Jahnson S, Aljabery F, et al. Standardized care pathways for patients with suspected urinary bladder cancer: the Swedish experience. Scand J Urol. 2022;56(3):227–232. https://doi.org/10.1080/21681805.2022.2058605 DOI: https://doi.org/10.1080/21681805.2022.2058605

Scilipoti P, Liedberg F, Garmo H, et al. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostatectomy. A nationwide population- based study. Scand J Urol. 2024;59:98–103. https://doi.org/10.2340/sju.v59.40001 DOI: https://doi.org/10.2340/sju.v59.40001

Åkerlund J, Sundqvist P, Ljungberg B, et al. Predictors for complication in renal cancer surgery: a national register study. Scand J Urol. 2023;58:38–45. https://doi.org/10.2340/sju.v58.12356 DOI: https://doi.org/10.2340/sju.v58.12356

Arnsrud Godtman R, Persson E, Bergengren O, et al. Surgeon volume and patient- reported urinary incontinence after radical prostatectomy. Population-based register study in Sweden. Scand J Urol. 2022;56(5–6):343–350. https://doi.org/10.1080/21681805.2022.2119270 DOI: https://doi.org/10.1080/21681805.2022.2119270

Gedeborg R, Sandin F, Thellenberg-Karlsson C, et al. Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden. Scand J Urol. 2023;58: 93-100 https://doi.org/10.2340/sju.v58.9572 DOI: https://doi.org/10.2340/sju.v58.9572

Bonde TM, Westerberg M, Aly M, et al. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non- metastatic prostate cancer treated with gonadotropin releasing hormone agonists. Scand J Urol. 2022;56(3):169–175. https://doi.org/10.1080/21681805.2022.2070275 DOI: https://doi.org/10.1080/21681805.2022.2070275

Gedeborg R, Lindhagen L, Loeb S, et al. Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer. Scand J Urol. 2022;56(2):104–111. https://doi.org/10.1080/21681805.2021.2019304 DOI: https://doi.org/10.1080/21681805.2021.2019304

Published

2024-12-12

How to Cite

Stattin, P. (2024). How to improve cancer care by use of guidelines and quality registers. Scandinavian Journal of Urology, 59, 190–192. https://doi.org/10.2340/sju.v59.42272

Issue

Section

Editorial comment